Mesothelioma
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for solid tumors (including mesothelioma) that…
Primary Outcome Measures Safety and feasibility of SynKIR-110 [ Time Frame: Date of enrollment through date of last patient visit, up to 36 months. ] • The incidence, frequency, and severity of TEAEs, incidence of AEs related to native mesothelin-expressing tissues, • Incidence of CRS and/or neurologic toxicity Secondary Outcome Measures Define the MTD or MFD of SynKIR-110 [ Time Frame: Date…
Primary Outcome Measures Dose limiting toxicity (DLT) of PRT3645 [ Time Frame: Baseline through Day 28 ] Dose limiting toxicity will be evaluated over the 28-day observation period Safety and tolerability of PRT3645: AEs, CTCAE Assessments [ Time Frame: Baseline through approximately 2 years ] Safety and tolerability will be evaluated by incidence of DLTs, laboratory measurements, severity of adverse events (AEs) according…
Mesothelioma is a rare cancer with a poor life expectancy. People diagnosed with pleural mesothelioma usually live for four to 18 months after diagnosis. The poor survival is a result of the aggressive nature of the cancer and that it is usually diagnosed at a late stage when it is less treatable. Once mesothelioma progresses,…
When mesothelioma patients are treated at mesothelioma specialty centers, they experience better care and survive longer. Kaiser Permanente Northern California Health System compared its performance before and after it transitioned into a specialty care center for mesothelioma. The doctors found a dramatic improvement in patients after the transition. Results were published in the Journal for…
Primary Outcome Measures Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time. [ Time Frame: 54 Months ] Secondary Outcome Measures Number of TTFields treatment-related SAEs, as assessed by the CEC, within total observation period, standardized to average annual incidences. [ Time Frame: 3 years + 18 months follow up ] Changes in quality of life…
A new tool to determine levels of asbestos exposure has been developed. The tool, created by Italian researchers, is known as a Retrospective Exposure Assessment (REA). The tool uses a microscope to determine how much asbestos is in lung tissue. The study wants to compare the actual level of asbestos in lung tissue to levels…
Primary Outcome Measures Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 24 months ] The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data Maximum Tolerated Dose (MTD) [ Time Frame: Up to 24 months ] The MTD will be determined using DLTs Incidence of Adverse Events [ Time Frame: Up to 24 months ] Safety and tolerability profile…
Researchers have found a treatment that can eradicate advanced stage mesothelioma tumors within a few days. The research is being done at Rice University and Baylor College of Medicine. The treatment utilizes implants known as “drug factories” and a checkpoint inhibitor drug. Mesothelioma is a tough to treat cancer of the mesothelium, which is a…
A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in Vienna, Austria. The two drugs…
